InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,648.40
(
1.01%
)
US TECH 100
18,955.60
(
-0.50%
)
Dow Jones
41,563.08
(
0.55%
)
Brent Oil
75.48
(
-2.22%
)
Bitcoin
58,953.83
(
-0.28%
)
Post# of 23979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

buckiii2

Send PM Follow Ignore
Followers 59
Posts 4696
Boards Moderated 0
Alias Born 04/27/2009

buckiii2

Re: None

Monday, 04/06/2015 5:35:13 PM

Monday, April 06, 2015 5:35:13 PM

Post# of 23979
Deutsche Bank: Buy Enanta Pharma And Its Near-Term Upside

In a report published Monday, Deutsche Bank analysts imitated coverage of Enanta Pharmaceuticals, Inc (NASDAQ: ENTA) with a Buy rating and a price target of $42.

Enanta is a small cap HCV company that is partnered with big cap Abbvie selling Viekira.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up